Knowledge-Based Design of Long-Chain Arylpiperazine Derivatives Targeting Multiple Serotonin Receptors as Potential Candidates for Treatment of Autism Spectrum Disorder

Abstract

Autism Spectrum Disorder (ASD) includes a group of neurodevelopmental disorders characterized by core symptoms such as impaired social interaction and communication, repetitive and stereotyped behaviors, and restricted interests. To date, there are no effective treatments for these core symptoms. Several studies have shown that the brain serotonin (5-HT) neurotransmission system is altered in both ASD patients and animal models of the disease. Multiple pieces of evidence suggest that targeting 5-HT receptors may treat the core symptoms of ASD and associated intellectual disabilities. In fact, stimulation of the 5-HT1A receptor reduces repetitive and restricted behaviors, blockade of the 5-HT2A receptor reduces both learning deficits and repetitive behavior, and activation of the 5-HT7 receptor improves cognitive performances and reduces repetitive behavior. On such a basis, a set of novel arylpiperazine derivatives have been synthesized by pursuing unprecedently reported activity profiles: dual 5-HT1A/5-HT7 receptor agonist properties and mixed 5-HT1A agonist/5-HT7 agonist/5-HT2A antagonist properties. Dual 5-HT1AR/5-HT7R agonists and the mixed 5-HT1AR agonist/5-HT7R agonist/5-HT2AR antagonists have been identified. These compounds are metabolically stable in vitro and have suitable central nervous system drug-like properties.